A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Context

Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge. Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy (PRLT) with small-molecule, urea-based agents labeled with the β-particle-emitting radionuclide lutetium-177 (¹⁷⁷Lu) is a promising new approach.

Objective

In this systematic review and meta-analysis, we evaluated the efficacy and toxicity of PRLT.

Evidence acquisition

A systematic search was performed in PubMed/Medline (last updated February 18, 2019). A total of 250 studies were reviewed, and 24 studies with 1192 patients were included in the analysis. Proportions of patients with ≥50% serum prostate-specific antigen (PSA) decrease, any PSA decrease, and any PSA increase were extrac

SUBMITTER: Sadaghiani MS 

PROVIDER: S-EPMC8206006 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature